AIMS
Despite continuous improvements in diagnostic tools, the diagnosis of acute myocardial infarction (AMI) is still based on electrocardiogram (ECG) and cardiac biomarkers supported by other non-invasive imaging techniques. However, ECG has limited sensitivity, while high-sensitivity troponin assays may show reduced...
F. Giacobbe, O. de Filippo, M. Petracca et al.· Cardiovascular Research· 0 citations
BACKGROUND
Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC-3 criteria to better classify procedural complications.
METHODS
We conducte...
F. Giacobbe, Francesco Bruno, M. Brero et al.· Journal of the American Hear...· 0 citations
In contemporary European practice, patients <50 yrs undergoing LVAD implant had high 5-yr survival approaching that reported in cohorts of patients listed for HT, which support further investigation of prolonged LVAD support before HT as a potential strategy to maximize lifetime benefit in selected motivated younger ca...
G. Gallone, K. Veen, A. Bernhardt et al.· European Journal of Cardio-T...· 0 citations
BACKGROUND
The Venous Excess Ultrasound (VExUS) score is increasingly used to assess systemic venous congestion, yet direct validation against invasively measured right atrial pressure (RAP) in pulmonary hypertension (PH) remains limited.
RESEARCH QUESTION
How accurate is the VExUS score to predict RAP in patients wi...
M. D'Alto, N. Cangiano, Antonio Orlando et al.· Chest· 0 citations
Vericiguat reduces cardiovascular death and heart failure (HF) hospitalization in high-risk patients with HF and reduced ejection fraction (HFrEF), but its non-invasive haemodynamic and remodelling effects in real-world practice remain incompletely characterized. We aimed to evaluate changes in non-invasive hemodynamic...
P. Bocchino, C. Carbonaro, G. Gallone et al.· American Journal of Cardiolo...· 1 citation
The addition of evolocumab reduced the total number of MACE, providing support for the role of intensive low-density lipoprotein cholesterol lowering to prevent first and subsequent MACE in patients at high cardiovascular risk and no prior MI or stroke.
José C. Nicolau, S. Murphy, Robert P. Giugliano et al.· Journal of the American Coll...· 1 citation
These results support using evolocumab to improve survival in high-risk patients who have not experienced a previous myocardial infarction or stroke, including those with high-risk diabetes without qualifying atherosclerosis with low-density lipoprotein-cholesterol ≥ 90 mg/dl or apolipoprotein B ≥ 80 mg/dl.
Robert P. Giugliano, E. Bohula, A. Bellavia et al.· Circulation· 0 citations
Most patients at high CV risk were not optimally managed, with low rates of LLT initiation, treatment intensification, LDL-C monitoring, and LDL-C goal attainment across 11 databases, highlighting a substantial unmet clinical need for improved guideline-based lipid management to prevent first major CV events in high-ri...
Q. Chan, J. Cegla, U. Laufs et al.· Clinical Research in Cardiol...· 0 citations
It is argued that current evaluation paradigms inadequately capture the uncertainty-intensive nature of athlete cardiovascular assessment and proposed the text-proxy paradigm, a governance-oriented framework in which LLMs operate as semantic integration layers that process clinician-verified and structured outputs gene...
Stefano Palermi, A. Saglietto, F. d'Ascenzo et al.· Progress in cardiovascular d...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
